Results 221 to 230 of about 48,203 (352)
Three-year clinical outcomes of transcatheter left atrial appendage occlusion. [PDF]
Zhang T +25 more
europepmc +1 more source
ABSTRACT Background EnSite X provides a module to filter oscillated generator impedance signals due to cardiac beating/respiration (averaged impedance drop, AID). TactiFlex ablation catheter Sensor Enabled (TFSE) is the latest product to incorporate a contact‐force sensor with a flexible tip but without lesion‐estimating parameters.
Masahide Harada +6 more
wiley +1 more source
Bailout Left Atrial Appendage Closure implantation following Left <i>atrial appendage perforation-</i>a case report. [PDF]
Alessandrini H +4 more
europepmc +1 more source
Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial [PDF]
Lucas V.A. Boersma +16 more
openalex +1 more source
ABSTRACT Introduction Approval timelines for ablation catheters differ across major markets, potentially delaying clinical access. This study aimed to quantify approval lags for contemporary ablation catheters across the EU, the US, and Japan. Methods We retrospectively identified therapeutic ablation catheters with documented approval dates in the ...
Gaku Oguri +2 more
wiley +1 more source
The Largest Systematic Review of Left Atrial Appendage Aneurysms: A Comprehensive Analysis of 216 Cases. [PDF]
Mihali K +7 more
europepmc +1 more source
Case-Based Discussion Regarding Challenges in Patient Selection and Procedural Planning in Left Atrial Appendage Occlusion [PDF]
Sidakpal Panaich +4 more
openalex +1 more source
ABSTRACT Background AVEIR DR, an industry‐first dual‐chamber leadless pacemaker (LP), provides continuous atrioventricular synchrony through implant‐to‐implant (i2i) communication between atrial and ventricular LP devices. It is important to evaluate the early real‐world comparative safety of AVEIR DR LP.
Monica Lo +10 more
wiley +1 more source
ABSTRACT Aims/Introduction While treatment for diabetic polyneuropathy (DPN) is still developing, progress has stagnated. The alignment between pathological neurodegeneration in DPN and patients' subjective symptoms is often low, yet these symptoms are frequently used for diagnosis.
Tatsuhito Himeno +14 more
wiley +1 more source

